<DOC>
	<DOCNO>NCT01010217</DOCNO>
	<brief_summary>The goal clinical research study learn safety give stem cell transplant tissue-mismatched donor , follow cyclophosphamide , patient certain type blood disorder blood cancer . Melphalan , thiotepa , fludarabine also give transplant . Researchers study health status patient 3 month transplant .</brief_summary>
	<brief_title>Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide</brief_title>
	<detailed_description>The Study Treatment : Cyclophosphamide design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . In study , researcher want learn cyclophosphamide help prevent graft-versus-host disease ( GVHD -- transplant immune tissue , white blood cell , attack tissue recipient 's body ) . Melphalan , thiotepa , fludarabine commonly use combination stem cell transplant . Study Treatment Administration : If find eligible take part study , receive chemotherapy 6 day : - You receive melphalan vein 30 minute Day -8 ( 8 day transplant ) . - You receive thiotepa vein 4 hour Day -7 . - You receive fludarabine vein 1 hour Days -6 , -5 , -4 , -3 . If thiotepa available , receive melphalan vein 30 minute Day -6 fludarabine vein 1 hour Days -5 , -4 , -3 , -2 . You receive total body irradiation ( TBI ) Day -1 . On Day 0 , receive donor 's stem cell vein . This may last anywhere 15 minute several hour . On Days 3 4 , receive cyclophosphamide vein 3 hour . You also receive mesna vein 30 minute every 4 hour total 10 mesna dos Days 3 4 . Mesna give low risk side effect bladder . Starting Day 5 , receive tacrolimus mycophenolate mofetil ( MMF ) help low risk GVHD . Tacrolimus give vein continuous infusion 2 week . After 2 week take tacrolimus vein , take tacrolimus mouth pill least 3 month . MMF give mouth , 3 time day , usually Day 35 . Starting Day 7 , receive filgrastim ( G-CSF ) day injection skin , blood cell count reach high enough level . Depending type disease , doctor may decide give rituximab vein several hour Days -13 , -6 , 1 , 8 . Rituximab give help body get rid abnormal white blood cell . Length Study Participation : You hospital 4 week transplant . You take study disease get bad . The study drug stop intolerable side effect occur . Follow-Up Visits : You ask stay close enough Houston able come back visit least 100 day transplant . At 1 , 3 , 6 , 12 month transplant , follow test procedure perform : - You physical exam . - Blood ( 4 tablespoon ) draw routine test . - You bone marrow biopsy/aspirate check status disease . If lymphoma aplastic anemia , may bone marrow biopsy/aspirate 3 , 6 , 12 month , doctor think need . - Blood ( 4 tablespoon ) draw measure tumor cell predict graft failure and/or relapse . - You may urine collect and/or scan perform x-ray , CT scan , and/or positron emission tomography ( PET ) scan . These scan urine test would do study doctor think need check status disease . - Blood ( 4 tablespoon ) draw check immune system . If AML , 2 month transplant , blood ( 4 tablespoon ) draw check immune system . If MM , bone survey year . If study doctor think need base side effect may , additional follow-up test perform . You may contact phone 1-2 time year ask status disease . These call take 10 minute complete . This investigational study . All drug use study commercially available FDA approve . However , investigational give high-dose cyclophosphamide prevent GVHD may occur stem cell transplant tissue-mismatched donor . Up 337 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients &lt; 55 year ( Myeloablative regimen # 1 ) &gt; 55 &lt; /= 75 year significant comorbidities ( Reduced intensity regimen # 2 ) old lack match related volunteer donor identify time transplant related haploidentical donor ( &lt; /= 7/8 allele match A , B , C , DR locus ) , 7/8 allele match related unrelated donor identify , match unrelated donor ( MUD ) . The patient must diagnose highrisk disease define follow : 2 . Acute lymphocytic leukemia ( ALL ) CR1 highrisk feature include adverse cytogenetics ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL gene rearrangement ; ALL second great remission ALL relapse disease , peripheral blood blast &lt; 1000/microliter , ALL patient must show response recent receive chemotherapy ; 3 . Acute myeloid leukemia ( AML ) CR1 intermediaterisk disease highrisk feature define : Greater 1 cycle induction therapy require achieve remission ; Preceding myelodysplastic syndrome ( MDS ) myeloproliferative disease ; Presence FLT3 mutation internal tandem duplication ; FAB M6 M7 classification ; Adverse cytogenetics , 5 , del 5q , 7 , del7q , abnormality involve 3q , 9q , 11q , 20q , 21q , 17 , +8 [ &gt; 3 abnormality ] , peripheral blood blast &lt; 1000/microliter , AML patient must show response recent receive chemotherapy ; 4 . AML second great remission , primary induction failure patient relapse disease , peripheral blood blast &lt; 1000/microliter ; patient &gt; 55 year &lt; /= 75 year need morphologic remission transplant ( &lt; 5 % blast ) . 5 . Myelodysplastic syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) intermediate2 high ; therapyrelated MDS 6 . Aplastic anemia Absolute neutrophil count ( ANC ) &lt; 1000 transfusion dependent fail immunosuppression therapy 7 . Chronic myeloid leukemia ( CML ) &gt; /=1st chronic phase , fail &gt; /=2 line tyrosine kinase inhibitor ; accelerate blast phase &gt; 30 % bone marrow blast ; 8 . Prior allogeneic stem cell transplant 6 month first transplant , remission . 9 . Chemotherapysensitive relapse lymphoma ( Complete partial response ) , Hodgkin 's nonHodgkin 's lymphoma , evidence `` bulky '' disease ( &gt; 10 cm diameter ) ; 10 . Patients chemosensitive CLL persistent recurrent disease fludarabinebased regimen , evidence `` bulky '' disease ( &gt; 10 cm diameter ) 11 . Patients poor prognosis multiple myeloma cytogenetics ( del13 , del 17p , ( 1 ; 14 ) ( 14 ; 16 ) hypodiploidy , advanced disease ( stage &gt; /=2 ) /or relapse autologous stem cell transplant . 12 . Patients myelofibrosis ( Lille &gt; 0 , transfusion dependency , progression blast phase ; however , remission AML ) CMML . These patient treat reducedintensity condition regimen # 2 subject stop rule group &gt; /= 55 year comorbidities . 13 . Zubrod performance status 01 Lansky PS great equal 70 % . 14 . Patients &gt; /=65 year old ageadjusted comorbidity index &lt; /= 3 . 15 . Available donor able undergo bone marrow harvest . For match unrelated donor transplant : Peripheral blood stem cell may collect donor unavailable bone marrow harvest adequate bone marrow collect . 16 . Bilirubin &lt; /= 1.5 mg/dl ( unless Gilbert 's syndrome ) , ALT AST &lt; /= 200 IU/ml . 17 . Serum creatinine clearance &gt; /=50 ml/min ( calculate CockcroftGault formula ) ; Creatinine child &lt; /=1.5 mg/dl &lt; /=2 time upper limit normal age ( whichever less ) ; 18 . Diffusing capacity carbon monoxide ( DLCO ) &gt; /= 45 % predict correct hemoglobin . For pediatric patient , unable perform pulmonary function , &gt; /= 92 % oxygen saturation pulse oximetry . 19 . LVEF &gt; /= 40 % . 20 . Patient patient 's legal representative , parent ( ) guardian provide write informed consent . Assent minor participant 's age least seven less eighteen year . 1 . HIV positive ; active hepatitis B C 2 . Patients active infection . The PI final arbiter eligibility . 3 . Liver cirrhosis great grade 1 stage 1 inflammation/fibrosis 4 . Uncontrolled CNS involvement tumor cell 5 . Patients AML must less 30 % bone marrow blast peripheral blood blast . 6 . History another primary malignancy remission least 3 year . ( The follow exempt 3year limit : noninvasive nonmelanoma skin cancer , fully excise melanoma situ [ Stage 0 ] , curatively treat localized prostate cancer , cervical carcinoma situ biopsy squamous intraepithelial lesion PAP smear . ) 7 . Positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 8 . Inability comply medical therapy followup .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hematologic Neoplasms</keyword>
	<keyword>Blood Disorders</keyword>
	<keyword>Blood Cancer</keyword>
	<keyword>Transplantation , Blood And Marrow</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>Aplastic anemia</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Myeloproliferative disease</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Mesna</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Mycofenolate mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>